So far, mTOR-targeted therapies are not in clinical use for first line therapy in glioma patients, nevertheless in case of tumor relapse or progression mTOR-targeted therapy regimens might become important therapeutic options. This evidence concerns the gene MTOR and central nervous system cancer.